1,608 Shares in Akero Therapeutics (NASDAQ:AKRO) Purchased by Victory Capital Management Inc.

Victory Capital Management Inc. acquired a new stake in Akero Therapeutics (NASDAQ:AKRO) in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 1,608 shares of the company’s stock, valued at approximately $31,000.

A number of other institutional investors also recently added to or reduced their stakes in AKRO. Cormorant Asset Management LP purchased a new stake in Akero Therapeutics in the 2nd quarter valued at about $14,704,000. Janus Henderson Group PLC bought a new position in shares of Akero Therapeutics during the 2nd quarter worth approximately $14,578,000. Hillhouse Capital Advisors LTD. bought a new position in shares of Akero Therapeutics during the 2nd quarter worth approximately $8,139,000. Hillhouse Capital Management LTD. acquired a new position in Akero Therapeutics during the 2nd quarter valued at approximately $5,698,000. Finally, Rock Springs Capital Management LP acquired a new position in Akero Therapeutics during the 2nd quarter valued at approximately $4,309,000. 37.34% of the stock is owned by institutional investors.

A number of research analysts have issued reports on the stock. Evercore ISI assumed coverage on shares of Akero Therapeutics in a research note on Monday, July 15th. They set an “outperform” rating and a $35.00 price target on the stock. Jefferies Financial Group assumed coverage on shares of Akero Therapeutics in a research note on Monday, July 15th. They set a “buy” rating and a $28.00 price target on the stock. Roth Capital assumed coverage on shares of Akero Therapeutics in a research note on Monday, July 15th. They set a “buy” rating and a $34.00 price target on the stock. Finally, JPMorgan Chase & Co. assumed coverage on shares of Akero Therapeutics in a research note on Monday, July 15th. They set an “overweight” rating and a $28.00 price target on the stock.

Shares of Akero Therapeutics stock opened at $18.25 on Friday. Akero Therapeutics has a 12-month low of $16.06 and a 12-month high of $30.30. The company’s 50 day moving average is $22.75.

Akero Therapeutics (NASDAQ:AKRO) last issued its quarterly earnings results on Monday, August 12th. The company reported ($2.21) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.36) by ($1.85). Equities research analysts expect that Akero Therapeutics will post -2.72 earnings per share for the current fiscal year.

Akero Therapeutics Company Profile

Akero Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development and commercialization of transformative treatments for serious metabolic diseases with high unmet medical need. Its lead product candidate is AKR-001, which completed Phase Ib clinical trial for the treatment of non-alcoholic steatohepatitis disease.

Featured Story: What is a price target?

Institutional Ownership by Quarter for Akero Therapeutics (NASDAQ:AKRO)

Receive News & Ratings for Akero Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akero Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.